Christi Shaw — Senior Vice President and President of Lilly Bio-Medicines at Eli Lilly and Company

Ms. Christi Shaw has been Senior Vice President and President of Lilly Bio-Medicines at Eli Lilly and Company since April 3, 2017. Ms. Shaw has been President of Novartis Corporation since April 2014. Ms. Shaw has been President and US Country Head of Novartis Pharmaceuticals Corporation since April 2014. She served as North American Region Head of Novartis Oncology at Novartis Pharmaceuticals Corporation. She started her career at Lilly in 1989. Ms. Shaw joined Novartis Oncology in July 2010, overseeing all commercial operations for the US and Canada. She has more than 25 years of experience in various commercial functions, along with a deep understanding of the US market. She has strong capabilities across Marketing, Sales, BD&L, Pipeline Development and Business Strategy. Prior to Novartis, she was at Johnson & Johnson as Vice President, New Business Development & Strategic Analytics for Ethicon. Ms. Shaw was responsible for leading Ethicon's franchise-wide business development initiatives, including licensing and acquisition and technology assessment, as well as the company's business information and analytics capabilities. Ms. Shaw spent two years as Vice President, Worldwide Marketing, Ethicon Products, where she worked with R&D to accelerate the pipeline, resulting in six product launches. She joined Johnson & Johnson in 2002 at Janssen Pharmaceuticals. During her tenure in that Corporation, she transitioned through a number of positions with increasing responsibility within Janssen Psychiatry, Ortho Women's Health & Urology and McNeil Pediatrics primarily within sales, strategic marketing and business development. She joined the device and diagnostic division at Ethicon in 2007. She started her career in Pharmaceuticals at Eli Lilly and Company where she spent 12 years. Ms. Shaw has an MBA from the University of Wisconsin and a BA degree from Iowa State University.